AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Stock Information for Tiziana Life Sciences Ltd
Loading
Please wait while we load your information from QuoteMedia.